CoVBio is a startup, most recent round Acquired.
CoVBio is a startup. CoVBio has been acquired.
CoVBio developed booster vaccines and therapeutics targeting SARS‑CoV‑2 and related sarbecoviruses, including a pan‑sarbecovirus booster vaccine intended to protect against future variants and animal-to-human crossovers. The company was acquired by Leyden Labs in 2024.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.